Welcome to our dedicated page for Nexgel news (Ticker: NXGL), a resource for investors and traders seeking the latest updates and insights on Nexgel stock.
NexGel, Inc. develops and commercializes healthcare, beauty and over-the-counter products built around high-water-content hydrogel technology for healthcare and consumer applications.
Company news commonly covers operating and financial results, hydrogel and biomaterial product activity, strategic partnerships, acquisition and licensing activity, financing arrangements, and governance changes. Recent updates also document the launch of BioNX Surgical following a completed license and asset acquisition of commercial-stage regenerative biomaterial products.
NEXGEL (NASDAQ:NXGL) announced it will report fourth quarter and full year 2025 financial results after market close on March 31, 2026. Management will host a conference call at 4:30 P.M. ET the same day and provide a live webcast and replay.
Dial-in numbers, replay access code 11161124, and a 90-day archived webcast will be available for investors and analysts.
NEXGEL (NASDAQ: NXGL) announced terms to license and acquire a portfolio of six commercial-stage regenerative biomaterial products from Celularity (NASDAQ: CELU).
Key terms: $15 million upfront cash plus up to $20 million in milestone payments tied to net sales. The company says the deal should roughly triple revenue to ~ $35 million and make NEXGEL immediately profitable upon closing. The portfolio targets tendon repair, skin grafts, and bone growth, includes decade-long clinical use and reimbursement pathways, adds commercial/scientific staff, and remains subject to customary closing and financing.
NEXGEL (NASDAQ: NXGL) signed a definitive agreement to license and acquire a portfolio of six commercial-stage regenerative biomaterial products from Celularity, a deal expected to approximately triple NEXGEL’s annual revenue to about $35 million and make the company immediately profitable upon closing.
The portfolio includes established products with existing insurance reimbursement, plans for three 510(k) filings in 2026–2028, and an experienced commercial team expected to join. The company anticipates approximately $14.9 million of additional financing in Q1 or early Q2 2026; closing remains subject to customary closing processes and financing.
NEXGEL (NASDAQ:NXGL) announced financing of $1.797 million related to a potential acquisition targeted to close in the first quarter of 2026. The transaction is subject to mutual due diligence and other conditions, and funds will be returned to the investor if the acquisition is not consummated. The investor may provide a potential additional $14.869 million pending completion of full due diligence. Palladium Capital Group acted as placement agent. The company said it will provide further details to shareholders during Q1 2026.
NEXGEL (NASDAQ:NXGL) announced that its previously disclosed spin-off, NexGelRx, received strategic investments from Eric Gruntfest and Ariel Imas of Diesis Holdings, LLC on Dec 16, 2025. In connection with the investment, NexGelRx appointed Eric Gruntfest as a board observer and strategic advisor.
Mr. Gruntfest brings over 20 years of experience in reimbursement strategy, payer solutions, and patient access, and currently serves as Managing Partner at Diesis Holdings and CEO of RMBB Health; his background includes senior roles at Medtronic, MiMedx, Shire, and Celgene. Management said his expertise will support commercialization and patient access for NexGelRx’s ultra-gentle hydrogel transdermal delivery products.
NEXGEL (NASDAQ:NXGL) announced the spin-off of select drug delivery assets into a new company, NexGelRx, which will develop prescription drug delivery products using NEXGEL’s hydrogel technology.
Under the agreement NEXGEL will receive a 5% global royalty in perpetuity, retain a 19.99% equity stake in NexGelRx that is non-dilutive for up to $8 million of capital investment, and serve as the exclusive manufacturer of hydrogel for NexGelRx. NexGelRx closed initial outside funding and will focus exclusively on Rx commercialization while NEXGEL remains focused on manufacturing and consumer products.
NEXGEL (NASDAQ: NXGL) reported third quarter 2025 results for the period ended September 30, 2025. Net revenue was $2.93 million, essentially flat year‑over‑year and sequentially. Gross profit was $1.24 million and gross margin improved to 42.4% from 39.3% in Q3 2024. Net loss attributable to NEXGEL stockholders was $0.65 million. EBITDA was ($0.55) million and Adjusted EBITDA was ($0.35) million, with Adjusted EBITDA narrowing sequentially. As of September 30, 2025, cash totaled approximately $938 thousand and restricted cash totaled $920 thousand related to $1 million non‑dilutive capital from STADA. Shares outstanding as of November 11, 2025: 8,143,133.
NEXGEL (NASDAQ:NXGL) will report third quarter 2025 financial results after market close on November 11, 2025. Management will host a conference call the same day at 4:30 P.M. ET to discuss the results and answer questions.
Call details: live dial-in 1-800-579-2543 (U.S. toll free) or 1-785-424-1789 (international); webcast via the company's Events and Presentations page. A replay is available through November 25, 2025 at 1-844-512-2921 (U.S. toll free) or 1-412-317-6671 (international) using code 11160116. An archived webcast will remain available for 90 days.
NEXGEL (NASDAQ: NXGL) announced that CEO Adam Levy will present at the LD Micro Main Event XIX conference in San Diego on October 20, 2025 at 11:30 a.m. PT. The presentation takes place at the Hotel Del Coronado in Track 4 and will be available via webcast.
Investors can access the live webcast at https://ir.nexgel.com/news-events/events-presentations. To request a one-on-one meeting with Mr. Levy during the event, contact KCSA Strategic Communications at Nexgel@KCSA.com.
NEXGEL (NASDAQ: NXGL) reported strong Q2 2025 financial results with revenue reaching $2.88 million, marking a significant 100.3% increase year-over-year. The company achieved substantial margin improvement with gross profit margin expanding to 43.6% from 20.3% in Q2 2024.
Key highlights include a reduced net loss of $0.67 million (vs. $0.89 million in Q2 2024) and improved Adjusted EBITDA of ($0.42) million. Post-quarter, NEXGEL secured a $1 million non-dilutive advance from STADA and raised $1.05 million in additional financing. The company maintains its 2025 guidance of $13 million in revenue and expects to achieve positive EBITDA during the year.